Some cautioned against reading too much into this analysis, since the main trial did not meet its primary endpoint.

The Evolut valves posed difficulties for operators trying to access the coronaries, a potential problem for younger patients.

One expert urged caution, saying, “Sometimes this smells like expanding the market” in the absence of high-quality RCT data.

New guidance on the treatment of peripheral artery disease (PAD) encourages collaborative vascular care to address health ...

Researchers saw some differences between valve types; while provocative, these data need confirmation, observers say.

The dedicated device can lacerate bioprosthetic leaflets poised to cause coronary obstruction—and does it quickly.

The simple tool includes just three factors, making it easy to use by the nonclinical staff most likely to use it.

The results are intuitive, but whether better stent expansion will translate into better clinical outcomes is still up for ...

The first trial to test shortened DAPT in coronary DCBs, REC-CAGEFREE II builds upon the evidence available for DES PCI.

BASEL, Switzerland—Low-dose colchicine doesn’t significantly reduce MACE in patients who have had a nonsevere ischemic stroke ...

The Indian-made valve, available in nine sizes, still needs to deliver on outcomes in a randomized trial, experts agreed.

The findings mirror research from other parts of the world, highlighting the need to address social determinants of health.